Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
The majority of biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A company starts generating revenues following a successful FDA approval and the launch of a drug. Under this circumstance, a high interest rate regime is detrimental to the biotech industry. The primary reason for the industry's weak performance year to date is that the Fed refrained from reducing the 23-year high interest rate, which is in the range of 5.25-5.5%, despite widespread expectation that the central bank will cut the benchmark lending rate by at least 75 basis points this year. Nevertheless, on Jun 12, in his post-FOMC meeting statement, Fed Chairman Jerome Powell indicated one cut of 25 basis points in the Fed fund rate in 2024. Moreover, the latest “dot-plot” of the FOMC meeting hinted at a full 1% rate cut across 2025. Consequently, the terminal rate of the Fed fund rate currently stands at 4.1% by the end of 2025. A low interest rate envi
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin TypesGlobeNewswire
- FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and OverGlobeNewswire
- Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association DermatologyGlobeNewswire
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255GlobeNewswire
ARQT
Earnings
- 8/14/24 - Beat
ARQT
Sec Filings
- 9/25/24 - Form 4
- 9/24/24 - Form 144
- 9/5/24 - Form 4
- ARQT's page on the SEC website